UT MD Anderson Cancer Center, Dept of Neuro-Oncology
Welcome,         Profile    Billing    Logout  
 6 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Weathers, Shiao-Pei
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT05053880: A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Recruiting
1b/2a
48
US
ACT001, ACT001 + Pembrolizumab
Accendatech USA Inc., C3 Research Associates, Avance Clinical Pty Ltd.
Recurrent Glioblastoma Multiforme(GBM)
11/22
11/23
NCT03174197: Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
80
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
06/25
06/25
NCT05039281: Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Recruiting
1/2
6
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib
M.D. Anderson Cancer Center
Recurrent Glioblastoma, Recurrent Gliosarcoma
12/25
12/25
NCT04991870: Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma

Recruiting
1
25
US
Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Allogeneic CB-derived Ex vivo-expanded NK Cells, CB-derived Expanded Allogeneic NK Cells, UCB-derived Expanded Allogeneic NK Cells, Umbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection, Surgical Resection
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma
01/27
01/27
NCI-2018-00872, NCT03452930: Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

Completed
1
5
US
Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Tinostamustine, 1H-Benzimidazole-2-heptanamide, 5-(Bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-, EDO-S 101, EDO-S-101, EDO-S101
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma
06/24
06/24
NCT04186832: Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy

Recruiting
N/A
50
US
FitBit, Pedometer, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Glioma, Radiation Therapy Patient
12/27
12/27
Cai, Doug
NCT05053880: A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Recruiting
1b/2a
48
US
ACT001, ACT001 + Pembrolizumab
Accendatech USA Inc., C3 Research Associates, Avance Clinical Pty Ltd.
Recurrent Glioblastoma Multiforme(GBM)
11/22
11/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Weathers, Shiao-Pei
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT05053880: A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Recruiting
1b/2a
48
US
ACT001, ACT001 + Pembrolizumab
Accendatech USA Inc., C3 Research Associates, Avance Clinical Pty Ltd.
Recurrent Glioblastoma Multiforme(GBM)
11/22
11/23
NCT03174197: Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Active, not recruiting
1/2
80
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
06/25
06/25
NCT05039281: Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Recruiting
1/2
6
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib
M.D. Anderson Cancer Center
Recurrent Glioblastoma, Recurrent Gliosarcoma
12/25
12/25
NCT04991870: Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma

Recruiting
1
25
US
Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Allogeneic CB-derived Ex vivo-expanded NK Cells, CB-derived Expanded Allogeneic NK Cells, UCB-derived Expanded Allogeneic NK Cells, Umbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection, Surgical Resection
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma
01/27
01/27
NCI-2018-00872, NCT03452930: Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma

Completed
1
5
US
Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Tinostamustine, 1H-Benzimidazole-2-heptanamide, 5-(Bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-, EDO-S 101, EDO-S-101, EDO-S101
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma
06/24
06/24
NCT04186832: Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy

Recruiting
N/A
50
US
FitBit, Pedometer, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Glioma, Radiation Therapy Patient
12/27
12/27
Cai, Doug
NCT05053880: A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Recruiting
1b/2a
48
US
ACT001, ACT001 + Pembrolizumab
Accendatech USA Inc., C3 Research Associates, Avance Clinical Pty Ltd.
Recurrent Glioblastoma Multiforme(GBM)
11/22
11/23

Download Options